Home » Stocks » VRNA

Verona Pharma PLC (VRNA)

Stock Price: $7.50 USD -0.16 (-2.09%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $7.61 +0.11 (1.47%) Jan 15, 6:43 PM
Market Cap 388.64M
Revenue (ttm) n/a
Net Income (ttm) -31.94M
Shares Out 105.33M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $7.50
Previous Close $7.66
Change ($) -0.16
Change (%) -2.09%
Day's Open 7.74
Day's Range 7.50 - 7.73
Day's Volume 29,501
52-Week Range 2.16 - 10.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

Top-line results expected in 2Q 2021 Top-line results expected in 2Q 2021

GlobeNewsWire - 1 week ago

LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, anno...

GlobeNewsWire - 1 month ago

Non-dilutive capital to provide further financial flexibility Non-dilutive capital to provide further financial flexibility

GlobeNewsWire - 2 months ago

LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, anno...

Seeking Alpha - 2 months ago

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Initiated ENHANCE Phase 3 clinical trials in COPD

GlobeNewsWire - 2 months ago

LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a further update with regards to its intend...

GlobeNewsWire - 3 months ago

Posters highlight ensifentrine’s potential to provide rapid benefits Posters highlight ensifentrine’s potential to provide rapid benefits

Zacks Investment Research - 3 months ago

Verona Pharma (VRNA) is developing twice-daily nebulized formulation of ensifentrine as potential maintenance treatment for COPD.

GlobeNewsWire - 3 months ago

LONDON and RALEIGH, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...

GlobeNewsWire - 3 months ago

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS ...

GlobeNewsWire - 4 months ago

LONDON and RALEIGH, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...

GlobeNewsWire - 4 months ago

Publication highlights ensifentrine’s potential to provide rapid symptom relief Publication highlights ensifentrine’s potential to provide rapid symptom relief

GlobeNewsWire - 4 months ago

LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...

GlobeNewsWire - 4 months ago

LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory ...

GlobeNewsWire - 4 months ago

LONDON and RALEIGH, N.C., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused o...

GlobeNewsWire - 4 months ago

New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients New subgroup analysis supports ensifentrine’s efficacy in symptomatic COPD patients

GlobeNewsWire - 4 months ago

Results expected in the first half of 2021 Results expected in the first half of 2021

Seeking Alpha - 5 months ago

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q2 2020 Results - Earnings Call Transcript

The Motley Fool - 5 months ago

The small drugmaker reported good news about new clinical studies for its lead pipeline candidate.

GlobeNewsWire - 5 months ago

Completed $200 million private placement post period

Zacks Investment Research - 5 months ago

Is (VRNA) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 5 months ago

LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) --  

Zacks Investment Research - 5 months ago

Top Ranked Momentum Stocks to Buy for August 6th 2020

Other stocks mentioned: OSB, PLT
GlobeNewsWire - 5 months ago

LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused...

Zacks Investment Research - 5 months ago

Top Ranked Momentum Stocks to Buy for August 4th

Other stocks mentioned: ABG, HOME, SFM
GlobeNewsWire - 5 months ago

LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory d...

Zacks Investment Research - 5 months ago

Top Ranked Momentum Stocks to Buy for July 31st

Other stocks mentioned: ABG, SFM, SSD
GlobeNewsWire - 5 months ago

LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory d...

Zacks Investment Research - 5 months ago

Top Ranked Momentum Stocks to Buy for July 29th

Other stocks mentioned: SCCO, SSD
Zacks Investment Research - 5 months ago

Top Ranked Momentum Stocks to Buy for July 28th

Other stocks mentioned: GTLS, PHM, WHR
Zacks Investment Research - 5 months ago

As of late, it has definitely been a great time to be an investor of Verona Pharma

GlobeNewsWire - 5 months ago

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. NE...

GlobeNewsWire - 6 months ago

LONDON, United Kingdom and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical...

GlobeNewsWire - 6 months ago

Funding to support Phase 3 ENHANCE clinical program in COPD Funding to support Phase 3 ENHANCE clinical program in COPD

GlobeNewsWire - 6 months ago

LONDON, July 06, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing in...

GlobeNewsWire - 8 months ago

LONDON, May 12, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and co...

Seeking Alpha - 8 months ago

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic

GlobeNewsWire - 9 months ago

LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...

GlobeNewsWire - 9 months ago

LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing an...

GlobeNewsWire - 9 months ago

Statistically significant and clinically meaningful improvements in lung function

GlobeNewsWire - 9 months ago

Statistically significant and clinically meaningful improvements in lung function

GlobeNewsWire - 10 months ago

LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing i...

GlobeNewsWire - 10 months ago

LONDON, March 05, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...

Seeking Alpha - 10 months ago

Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Vectoring In On Verona Pharma

GlobeNewsWire - 11 months ago

Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms Paper demonstrates ensifentrine’s potential in improving lung function and quality of life s...

GlobeNewsWire - 11 months ago

LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings

GlobeNewsWire - 11 months ago

Dr. David Zaccardelli appointed President and Chief Executive Officer

About VRNA

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical... [Read more...]

Industry
Biotechnology
IPO Date
Apr 27, 2017
CEO
David Zaccardelli
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
VRNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Verona Pharma stock is "Strong Buy." The 12-month stock price forecast is 18.80, which is an increase of 150.67% from the latest price.

Price Target
$18.80
(150.67% upside)
Analyst Consensus: Strong Buy